Core Viewpoint - The innovative drug sector is experiencing a rebound in both Hong Kong and A-share markets, driven by recent positive developments and increased investor interest in innovative drug ETFs [1][3][5]. Group 1: Market Performance - Hong Kong's innovative drug sector saw significant gains, with companies like InnoCare Pharma-B rising by 8% and Lepu Biopharma-B increasing over 5% [1]. - The A-share market's only drug ETF (562050) reached a premium of 1.67%, with leading stocks like Zai Lab Ltd. rising over 4% [3][12]. - The Hong Kong innovative drug ETF (520880) experienced a net subscription for nine consecutive days, with its fund size reaching a new high of 4.178 billion [5][13]. Group 2: Regulatory Developments - The new national medical insurance catalog added 111 new drugs launched within the last five years, including 50 first-class new drugs, marking a historical high in both quantity and proportion [7][15]. - Upcoming industry events, such as the January JPM conference and significant business development transactions, are expected to provide positive catalysts for the sector [15]. Group 3: Investment Opportunities - The Hong Kong innovative drug ETF (520880) is highlighted as a top choice for investors, offering unique advantages such as a pure focus on innovative drugs and a high concentration of leading companies, with over 72% of the top ten innovative drug leaders [15][16]. - For those looking to mitigate volatility while investing in innovative drugs, the only drug ETF in the market (562050) is recommended, which includes a significant portion of traditional Chinese medicine to provide stability [16].

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a continuous pullback, attributed to three main factors: profit-taking by investors as the year-end approaches, liquidity tightening due to various monetary policy changes, and disappointing BD events for some companies [1][3][4]. Group 1: Market Dynamics - Investors are showing a strong tendency to realize profits as the year-end approaches, leading to a decline in market risk appetite [1][3]. - Liquidity in the Hong Kong market is tightening due to the Federal Reserve's interest rate cuts, rising expectations of interest rate hikes by the Bank of Japan, and a slowdown in southbound capital inflows [1][3]. - Some industry-specific BD events have underperformed expectations, negatively impacting market sentiment [1][3]. Group 2: Investment Opportunities - Despite the current market pullback, it is viewed as a short-term risk release that does not alter the narrative of accelerated nationalization, technological breakthroughs, and payment system innovations in the innovative drug sector [1][4]. - The Hang Seng Innovative Drug ETF (520500) has seen a net inflow of 235 million yuan over six consecutive trading days, reaching a historical high of 1.251 billion shares since its inception [4]. - The ETF has an average daily trading volume of 729 million yuan since Q4 2025, indicating substantial scale and liquidity [4]. Group 3: Future Outlook - Tianfeng Securities suggests that after a systematic asset value reassessment in 2025, the main theme for innovative drug investments will be the reduction of risks, leading to enhanced predictability and sustained competitiveness for companies [4]. - The National Medical Security Work Conference held on December 13, 2025, encouraged the inclusion of more reasonable medical expenses outside the basic medical insurance catalog into commercial health insurance, which is expected to boost investment in innovative drugs [4].

Group 1 - The core viewpoint is that by 2026, the focus in the innovative drug market will shift from "BD supremacy" to "data supremacy," emphasizing the importance of clinical data and commercial capabilities in realizing revenue growth [1] - The pharmaceutical industry is expected to experience a reversal in 2025, led by innovative drugs, with significant benefits extending to the CXO and upstream supply chain, as well as notable gains in secondary sectors [2] - The Hong Kong stock market has seen remarkable performance in innovative drugs, with a peak increase of over 80% year-to-date, making it one of the most关注板块 in the first half of the year [2] Group 2 - The core catalysts for innovative drugs include policy support and the realization of BD opportunities, with significant transactions such as those by 3SBio and Innovent Biologics, which have seen upfront payments exceeding $1 billion [2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, aimed at addressing the gap in coverage for high-value innovative drugs [2] - By November 13, 2025, the number of license-out transactions by Chinese pharmaceutical companies has rapidly increased, with total upfront payments reaching $6.298 billion, a 53% year-on-year increase, and total transaction amounts reaching $118.862 billion, a 125% year-on-year growth [3]

Core Viewpoint - The Hong Kong stock market for innovative drugs continues to decline, with the Hang Seng Index falling below the six-month moving average, indicating ongoing adjustments in the sector [1][3]. Market Performance - On December 9, the Hong Kong innovative drug ETF (520880) experienced a decline of 1.99%, marking two consecutive days of losses, with a trading volume of 283 million yuan [1]. - Major stocks within the ETF saw significant declines, including Kangfang Biotech down 4%, Sanofi Biotech down 3.63%, and Innovent Biologics down 1.4% [1]. Investment Opportunities - Analysts suggest that the current market conditions may present a favorable opportunity for long-term investment in core innovative drug assets, as the index has retraced over 18% since early September, indicating a sufficient adjustment and risk release [3]. - There are positive signals in the funding landscape, with over 56 million yuan net subscriptions for the innovative drug ETF on the previous day, the highest in nearly a month, indicating strong buying interest [4]. Policy Developments - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [5]. Business Development - Kelun-Biotech has granted exclusive rights to Crescent for the development of ADC drug SKB105 outside Greater China, along with exclusive rights for CR-001 bispecific antibody in Greater China, which includes an upfront payment of 80 million USD and potential milestone payments of up to 1.25 billion USD [6]. - Analysts recommend focusing on innovative drug companies with rich pipeline layouts, high potential single products, and leading technology platforms [6]. ETF Characteristics - The Hong Kong innovative drug ETF (520880) has a significant concentration in leading companies, with the top ten holdings accounting for over 72% of the index, showcasing the strength of the innovative drug sector [7]. - The ETF has a total market value of 2.142 billion yuan and has the highest liquidity among similar ETFs, with an average daily trading volume of 458 million yuan since its inception [7].

Core Viewpoint - The Hong Kong innovation drug sector is experiencing a downturn, with the Hong Kong Stock Connect Innovation Drug ETF (520880) declining over 2% and major stocks like Kangfang Biotech and 3SBio dropping more than 5% [1][3] Group 1: Market Performance - The Hong Kong innovation drug sector has entered a phase of adjustment since early September, with the Hong Kong Stock Connect Innovation Drug ETF (520880) index retreating over 19%, indicating that previous high risks have been sufficiently released [3] - There is a surge in "bottom-fishing" capital, with over 56 million yuan entering the market recently, leading to a spike in the premium of the Hong Kong Stock Connect Innovation Drug ETF [1][3] Group 2: Policy and Market Opportunities - A favorable policy announcement was made with the release of the 2025 National Medical Insurance Drug List, which added 114 new drugs, including 50 innovative drugs, achieving an overall success rate of 88%, significantly higher than the 76% in 2024 [5][6] - The introduction of the first version of the "Medical Insurance + Commercial Insurance Dual Directory" by the National Medical Insurance Bureau is expected to boost investment enthusiasm in innovative drugs [6] Group 3: Investment Insights - Analysts suggest that the current market conditions may present a good opportunity for medium to long-term investment in core innovative drug assets [3][6] - The Hong Kong Stock Connect Innovation Drug ETF (520880) is highlighted for its unique advantages, including a pure focus on innovative drug companies, a high concentration of leading firms (over 72% in the top ten), and better risk control through the management of less liquid stocks [6][7]

Core Viewpoint - The Hong Kong innovation drug sector is experiencing a downturn, with the Hong Kong Stock Connect Innovation Drug ETF (520880) declining over 2% and major stocks like Kangfang Biotech and 3SBio dropping more than 5% [1][9]. Group 1: Market Performance - The Hong Kong innovation drug sector has entered a phase of adjustment since early September, with the ETF index retreating over 19%, indicating that previous high risks have been sufficiently released [3][12]. - There is a surge in "bottom-fishing" capital, with over 56 million yuan entering the Hong Kong Stock Connect Innovation Drug ETF recently [1][9]. Group 2: Investment Opportunities - The National Healthcare Security Administration released the first version of the "Medical Insurance + Commercial Insurance Dual Directory," which may boost investment enthusiasm for innovative drugs in the short term [2][11]. - The 2025 National Medical Insurance Drug List successfully added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [4][11]. - Analysts suggest that the current market conditions may present a favorable opportunity for long-term investment in core innovative drug assets [3][12]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovation Drug ETF (520880) is the largest in its category, with a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception [7][15]. - The ETF's index has three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms with over 72% weight in the top ten stocks, and employs measures to control risks associated with less liquid stocks [5][6][13].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]

Investment Rating - The report maintains an investment rating of "Positive" for the pharmaceutical and biotechnology industry [2]. Core Viewpoints - The recent release of the "Medical Insurance + Commercial Insurance Dual Directory" by the National Medical Insurance Administration is expected to boost investment enthusiasm for innovative drugs. The report suggests focusing on investment opportunities in innovative drugs, CXO, and the upstream life sciences industry chain [3][9]. - The pharmaceutical sector is currently experiencing a lack of clear market direction, with the pharmaceutical commercial sector leading in performance. Notable stocks include Haiwang Biological (up 55.59%), Ruikang Pharmaceutical (up 36.54%), and Yue Wannianqing (up 15.37%) [3][9]. - The report emphasizes the importance of companies with stable dividends and operational improvements, as well as potential turning points in high-end medical devices [3][11]. Summary by Sections 1. Market Performance - The pharmaceutical and biotechnology sector's return was -0.74% last week, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices. The pharmaceutical commercial sector had the highest weekly return at 5.19% [3][7]. - Over the past month, the sector's return was -2.35%, also ranking 20th among sub-industry indices, with the pharmaceutical commercial sector leading at 5.78% [3][7]. 2. Innovative Drugs - The report recommends focusing on companies with leading product pipelines and market potential, including Innovent Biologics, 3SBio, Hengrui Medicine, and others [3][9][10]. 3. CXO and Upstream Life Sciences - Key CXO companies to watch include WuXi AppTec, WuXi Biologics, and others. The report also highlights clinical CRO leaders and resource-based CXOs [10]. 4. High-End Medical Devices - The report identifies several companies in the high-end medical device sector that may benefit from market recovery and increased demand, including Mindray Medical and others [11]. 5. Valuation Metrics - The current PE (TTM) for the pharmaceutical and biotechnology industry is 29.27 times, which is below the historical average of 30.88 times over the past five years [12][15].

Group 1 - The core viewpoint indicates that there is a strong focus on upcoming domestic and overseas meetings, particularly the Federal Reserve's interest rate decision, leading to a cautious market sentiment and reduced trading volume [1] - The domestic real estate sector is weakening, and the recovery is slightly below expectations, suggesting that proactive policies are likely to be implemented [1] - The Federal Reserve's direction towards interest rate cuts remains unchanged, which is expected to positively influence market conditions [1] Group 2 - The investment strategy includes a high proportion of high-quality combinations at 25% and low-quality combinations at 30%, indicating a balanced approach to risk and return [1] - There is a positive outlook on the innovative pharmaceutical investment sector, with adjustments made to include the "Jia Shi Zhong Zheng Hong Guo Tong Innovation Drug ETF" in the portfolio [1][3] - Current market indicators show a valuation temperature of 47.39°, a fear and greed index of 38, and a stock-bond value ratio temperature of 44°, suggesting that the stock market valuation is moderate [1]